Dual PI3K/mTOR inhibitors show less toxicity in patients, furthermore, their clinical efficacy is mainly related to genetic alterations e.g. PI3KCA, PTEN mutations which could suggest possible mTORI sensitivity of tumours and could not lower the recurrence. The gene discussed is PTEN; the disease is neoplasm.